Pei Kan

Dr. Kan has been working in the pharmaceutical industry for more than 20 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 10 patents related to drug delivery, some of which have been used in clinical products. He is now the President of Pharmosa and has served in Taiwan Liposomal Company (TLC) and Industrial Technology Research Institute (ITRI). He has led the development of new formulation projects, and completed more than 5 products for filing IND, BioIND, and ANDA products in Taiwan, China, United States, Japan, and Europe. He graduated from National Tsinghua University and completed post-doctoral research at Tsukuba University in Japan.